Home » Topics » BioWorld Science

BioWorld Science
RSS

Preliminary results from phase I pivotal study of Tonmya

May 25, 2018

First patient dosed in first-in-human trial of MCLA-158 in solid tumors

May 25, 2018

FDA approves Palynziq for adults with phenylketonuria

May 25, 2018

New prostate cancer model generated through Pmepa1 gene knockout

May 25, 2018

FDA grants fast track designation for KB-103

May 25, 2018

Alliance between Bicycle Therapeutics and ThromboGenics sees milestone and expansion

May 25, 2018

PACIFIC trial of Imfinzi in NSCLC meets second primary endpoint of overall survival

May 25, 2018

Phase III iLLUMINATE trial of Imbruvica plus Gazyva in first-line CLL/SLL meets primary endpoint

May 25, 2018

Portola Pharmaceuticals receives milestone payment following Andexxa approval

May 25, 2018

Celon Pharma evaluates 5-HT6 receptor antagonist PZ-KKN-94 in vitro and in vivo

May 25, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...